In the presence of the inhibitor, BMAL1 and PPARa oscillations were found to be fine-tuned in AML and CLL (Figure 5) patient samples when compared to non-treated patient samples (Figure 4). The gene discussed is BMAL1; the disease is B-cell chronic lymphocytic leukemia.